Cannabidiol (CBD) is a massive market and represents an unprecedented stock growth opportunity for investors. CBD does not get you high, has incredible health benefits and can be used as an input product in a wide variety of consumer goods. From food products to cosmetics, CBD has vast applications and this makes the opportunity to invest in the sector incredibly exciting.

That’s why we’re highlighting Real Brands, Inc. (RLBD). RLBD successfully launched their CBD Pharmacy® brand at the beginning of the year and has not released any news since. After their initial release of these cartridges the company quickly sold out, leading to this scaled up roll out. With that in mind, there is potentially some news coming soon following up on this announcement.

A few months ago the FDA got a unanimous vote by their federal advisory committee to recommend approval of a pharmaceutical CBD oil known as Epidiolex, which can be used to treat certain rare forms of epilepsy. As cannabis becomes legal nationwide, the industry surrounding it will continues to expand. Many politicians now campaign on a platform of total cannabis legalization since it’s such popular a stance with a majority of the country.

These stocks have investors excited: Real Brands, Inc. (RLBD), CV Sciences, Inc. (CVSI), Kush Bottles, Inc. (KSHB), Hemp, Inc. (OTC PINK: HEMP), INSYS Therapeutics, Inc . (INSY).

Real Brands, Inc. (RLBD)
Market Cap: $2.747M, current share price: $0.0209

Real Brands, Inc. is a brand building company in the Legal Hemp and Cannabis industry. The company acquisition strategy is for accretive acquisitions of trademarks, patents, other IP and related business opportunities that can be efficiently integrated into the portofolio infrastructure and financial capabilities so that the company can benefit from the gross profit contribution from distribution, licensing, joint ventures and other opportunities. Real Brands recently acquired the Omega Hemp Water™ trademark from Alkame Holdings, Inc. and the CBD Pharmacy® trademark as well as four (4) Colorado trademarks (Marijuana Cigarettes, Cannabis Cigarettes, Hemp Cigarettes and Cannabis Smoke Tobacco) and four (4) utility patents (An Inhaler for the consumption of Cannabinoids, Cannabis Infused Chewing Composition, A Method of Manufacturing a Smokable Cannabis Product and Cannabis Smokeless Tobacco).

CV Sciences, Inc. (CVSI)
Market Cap: $471M, current share price: $4.75

CV Sciences, Inc. is a life science company that operates through two segments, specialty pharmaceuticals and consumer products. They focus on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction.

Kush Bottles, Inc. (KSHB)
Market Cap: $427M, current share price: $5.41

Kush Bottles, Inc. is a dynamic sales and distribution platform that provides unique products and services for both businesses and consumers in the cannabis industry.

Hemp, Inc. (HEMP)
Market Cap: $24M, current share price: $0.03

Hemp, Inc. long-term goal is to be the leader in the industrial hemp industry in America, which is now estimated to be over $500 Million. Hemp, Inc.’s mission is to provide green solutions that help make the world a better place to live. They support products that are eco friendly, organic, healthy, and solutions that replace many petroleum-based products. Eventually, the company will produce fiber materials for the paper and fabric industries, and other industries that utilize materials from hemp to make products such as plastics, building materials, health and beauty related products and more. Hemp, Inc. plans to purchase, acquire and/or joint venture with complimentary companies across various sectors of the hemp industry in an effort to build a portfolio of synergistic businesses that will bring Hemp, Inc. cash flow, revenues, value, and position us as a leader in the industrial hemp industry.

INSYS Therapeutics, Inc . (INSY)
Market Cap: $632M, current share price: $8.29

Insys Therapeutics, Inc., is a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi.

Disclaimer: Vista Green simply supplies information in our shared and posted articles. What our readers do with that information is their use of free will. We would be more than happy to help anyone who wishes to invest in the market however, and if that is something our readers would like to discuss, they are encouraged to contact us here; Vista Green LLC

Original article here;


    CBD Companies On Massive Uptrends
    marijuana financial opportunities